Holen Sie sich die Stockscreener-App
1.36
6.21%
-0.09
Schlusskurs vom Vortag:
$1.45
Offen:
$1.35
24-Stunden-Volumen:
1.41M
Relative Volume:
0.96
Marktkapitalisierung:
$25.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-26.49%
1M Leistung:
-40.61%
6M Leistung:
-30.26%
1J Leistung:
-92.44%
1-Tages-Spanne:
$1.27
$1.49
1-Wochen-Bereich:
$1.27
$1.858
52-Wochen-Spanne:
$0.73
$18.50
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Vergleichen Sie CLDI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.36 | 25.63M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics CEO Allan Camaisa sells $16,200 in stock - Investing.com
Calidi Biotherapeutics prices $7.5M secondary offering - MSN
Calidi Biotherapeutics Inc (CLDI-A) QuotePress Release - The Globe and Mail
Calidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care - Barchart
UMACUnusual Machines, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics (NYSE American: CLDI) Shares Data Supporting Proprietary Systemic Antitumor Platform - Barchart
Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock - MSN
Calidi Biotherapeutics (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering - Barchart
If You Don’t Buy Calidi Biotherapeutics Inc (AMEX: CLDI) Now, You’ll Kick Yourself Later - Stocks Register
Calidi Biotherapeutics Reveals Promising Virotherapy Data - TipRanks
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer - EIN News
Calidi presents data on RTNova systemic technology in metastatic lung cancer - TipRanks
Calidi Bio's RTNova Shows Promise in Metastatic Lung Cancer Treatment Breakthrough | CLDI Stock News - StockTitan
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock - The Manila Times
Calidi Biotherapeutics Raises $7.5M Through Public Offering of 4.4M Shares | CLDI Stock News - StockTitan
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
SEC Form 424B5 filed by Calidi Biotherapeutics Inc. - Quantisnow
Calidi prices 4.4M shares at $1.69 in public offering - TipRanks
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock - The Manila Times
Calidi Biotherapeutics Raises $7.5M in Public Offering for Clinical Trials | CLDI Stock News - StockTitan
Calidi announces common stock offering, no amount given - TipRanks
Calidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News - MarketWatch
Calidi Biotherapeutics plans stock offering - Investing.com India
Calidi Biotherapeutics plans stock offering By Investing.com - Investing.com Canada
Calidi Biotherapeutics Announces Proposed Public Offering - The Manila Times
Calidi Biotherapeutics Launches Public Stock Offering to Fund Corporate Growth | CLDI Stock News - StockTitan
Calidi Biotherapeutics Advances with FDA Clearance and Funding - TipRanks
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - The Manila Times
Calidi Biotherapeutics’ $2.1 Million Shares Offering - Global Legal Chronicle
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Calidi Biotherapeutics (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics’ (NYSE American: CLDI) Groundbreaking Cancer Treatment on RedChip’s Bloomberg TV Program - Barchart
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Calidi to present data supporting RTNova at upcoming conferences - TipRanks
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences - The Manila Times
Calidi to sell 2.05M shares at $1.00 in registered direct offering - Yahoo Finance
Calidi Biotherapeutics stock tumbles on $2M securities offering - MSN
CLDI stock touches 52-week low at $0.95 amid sharp annual decline By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.95 amid sharp annual decline - Investing.com
Why Calidi Biotherapeutics (CLDI) Stock Is Down 13% - Benzinga
Calidi Biotherapeutics secures $2 million in equity financing - Investing.com
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times
Calidi Biotherapeutics Faces Warrant Delisting by NYSE - Yahoo Finance
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) - ForexTV.com
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
Kapitalisierung:
|
Volumen (24h):